Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Reduce Downstream Processing Costs for mAbs by Switching to Tosoh’s 2-Step Platform

Introduction

Downstream processing is responsible for up to 80 percent of the entire production costs of biotherapeutics. Given the current drive to reduce the cost of manufacturing for biological therapeutics, streamlining downstream processing is a necessity for chromatographers and process engineers.

In this study, we showcase the benefits of Tosoh’s 2-step process for the purification of monoclonal antibodies (mAb) in comparison to the standard industrial process. Combining high-performance Protein A capturing and a single polishing step on salt-tolerant anion exchange resin, we could reduce the downstream costs by 45 % and increase the production output by 58 %.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register